Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies
about
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potentialReactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical IndicationsEffects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockadeChronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats.Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis.PDE-5 inhibition impedes TSP-1 expression, TGF-beta activation and matrix accumulation in experimental glomerulonephritis.Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme.New perspectives for the treatment of pulmonary hypertensionA Rho-kinase inhibitor, soluble guanylate cyclase activator and nitric oxide-releasing PDE5 inhibitor: novel approaches to erectile dysfunction.Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle.Cyclic nucleotide signalling in kidney fibrosis.Soluble guanylyl cyclase: physiological role as an NO receptor and the potential molecular target for therapeutic application.Cobinamides are novel coactivators of nitric oxide receptor that target soluble guanylyl cyclase catalytic domain.Genetic modifiers of hypertension in soluble guanylate cyclase α1-deficient micePathophysiology of hypertension in the absence of nitric oxide/cyclic GMP signaling.The future of the oral pharmacotherapy of male erectile dysfunction: things to come.The sGC activator BAY 60-2770 has potent erectile activity in the rat.Inhalative and intravenous stimulation of soluble guanylate cyclase reduces pulmonary vascular resistance and increases cardiac output in experimental septic shock.Novel therapeutic strategies targeting vascular endothelium in essential hypertension.Soluble guanylate cyclase: a potential therapeutic target for heart failure.Stimulators of soluble guanylyl cyclase: future clinical indicationsNew medical therapies for heart failure.Riociguat (BAY 63-2521) and aspirin: a randomized, pharmacodynamic, and pharmacokinetic interaction study.NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size.Direct sGC activation bypasses NO scavenging reactions of intravascular free oxy-hemoglobin and limits vasoconstriction.Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress.Analysis of responses to glyceryl trinitrate and sodium nitrite in the intact chest rat.Soluble guanylate cyclase: an old therapeutic target re-visited.Dynamic change of heme environment in soluble guanylate cyclase and complexation of NO-independent drug agents with H-NOX domain.Synthesis and antimicrobial activity of some new heterocycles incorporating the pyrazolopyridine moiety.A Soluble Guanylate Cyclase Activator Inhibits the Progression of Diabetic Nephropathy in the ZSF1 Rat.Urinary cGMP predicts major adverse renal events in patients with mild renal impairment and/or diabetes mellitus before exposure to contrast medium.
P2860
Q24656131-7C567DA2-A592-4AF1-9B24-60D91E19C870Q27024762-0BE8A1FB-3E7C-451F-8351-5B3126174928Q28482185-81C7C70B-1AE4-4776-9651-083E5F02F1E2Q30315850-BD98F5A2-81E1-4131-B8E3-1E6C5D2A8C45Q33209298-AEDEA569-E953-49D4-A5D7-42D04B238B60Q33348441-4E60D629-79D6-45B9-87AE-9B992ABD7AC1Q34720361-6A299FFA-1003-4A74-93FB-D174B229C8D2Q34903204-63C596D2-4694-41B5-B4CA-43491ADB5324Q35001011-9C5A904A-CCC3-472E-A6D4-0D13D7ABBB2FQ35010064-604CF0E1-8A22-4464-B835-63C71E9FD3ECQ35044464-AFD886F1-4953-491C-9631-C837B6091AA0Q35138860-702DEE00-51AA-47BF-A24E-D1A4BB6946E6Q35206512-4635D54A-E015-45B5-AD3F-ED192159873FQ35776824-4BAB907C-0CC0-4EB2-B7C4-2759175D23A1Q36005369-053CC972-6A8F-4327-ADB2-672616BE5FBCQ36532454-4E5E0BE8-589A-4A08-9E5A-814EA54C1925Q36866594-E8837655-7CD9-4D01-A5AF-F177AD067700Q36923923-EFCB0F4E-D69A-4AE0-9BD9-D93145572881Q37734554-3EE2337B-9DA5-4C3B-824F-2C5D7C0B30C3Q37798006-EDBB1BC0-D907-48D1-B1DD-7FEDA5D2B5E3Q38012596-26418A91-7C47-4238-BB9B-2D198D4A610EQ38093420-4D74A8D6-FDF3-47D0-88CC-C0036C9B2ED0Q38594785-A5EE9C3D-61EA-43FE-BB19-A3A280D4114CQ41166010-5F9CDDFC-A275-416C-B2B8-1395A34CE720Q41879996-3CE4E213-4719-4BF2-B04D-88D27EF3955AQ41894813-EAE82794-1D15-48FB-B9F4-0FD3EE6AE2CDQ42075795-26BDB692-45FF-4228-9C2E-214E16F15B2AQ42502151-B66E2E62-3763-488F-B9D7-19FAFC5A174EQ43263737-55393778-701D-46DA-B4EA-B661EA10B6FFQ43862233-804CFDDA-068B-48A9-B9CA-864AE9B93DC6Q46189381-0589FC55-7979-4FCA-925B-3C63A8794F19Q53644051-04DBBDEF-454A-4D49-BAD9-ED030DA67C68Q55113144-8C9CB946-99CA-4133-976A-8B54280599F3
P2860
Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Cardiovascular actions of a no ...... , BAY 41-8543: in vivo studies
@en
type
label
Cardiovascular actions of a no ...... , BAY 41-8543: in vivo studies
@en
prefLabel
Cardiovascular actions of a no ...... , BAY 41-8543: in vivo studies
@en
P2093
P2860
P356
P1476
Cardiovascular actions of a no ...... , BAY 41-8543: in vivo studies
@en
P2093
Elisabeth Perzborn
Elke Stahl
Klaus Dembowsky
Matthias Schramm
P2860
P304
P356
10.1038/SJ.BJP.0704483
P407
P577
2002-01-01T00:00:00Z